WO2003090775A1 - Foods and drugs containing silkworm and wild silkworm silk powder for antidementia effect and improving memorization learning - Google Patents
Foods and drugs containing silkworm and wild silkworm silk powder for antidementia effect and improving memorization learning Download PDFInfo
- Publication number
- WO2003090775A1 WO2003090775A1 PCT/JP2002/009051 JP0209051W WO03090775A1 WO 2003090775 A1 WO2003090775 A1 WO 2003090775A1 JP 0209051 W JP0209051 W JP 0209051W WO 03090775 A1 WO03090775 A1 WO 03090775A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silkworms
- wild
- silkworm
- silk powder
- learning
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a method for improving the anti-dementia effect and the memory learning effect of mammals including humans.
- Silkworm and silkworm silk powders are pulverized by various manufacturing techniques, and the amino acid composition of the low molecular weight pulverized protein is a known amino acid composition because it is a protein at the mouth of the fiber. It is used for foods and cosmetics as its usage.
- amino acids constituting the protein of the fibular mouth such as glycine, alanine, serine, and tyrosine are abundant, anti-dementia effects and memory learning improvement effects are expected for silkworms and silkworm wild silkworms.
- Silkworms and wild silkworm silk powder prepared according to known production methods were allowed to freely ingest mice (five-week-old ICR female) orally as an aqueous solution, and tap water was used as a control.
- Serum albumin (adopted as brush-po) Oral administration of aqueous solution. Disclosure of the invention
- Fig. 1 This is the result of performing a step-through passive avoidance experiment for two days 30 days after the start of ingestion.
- scopolamine which causes temporary dementia
- reproduction the time until the door is opened and a dark room is measured.
- data analysis is performed using nonparametric analysis. Tests within the same county use the Wilcoxon signed rank test, and tests between different groups use the Mann-Whitney U test to find significant differences.
- the example shown in FIG. 1 is the result of the memory ability (sec) in the acquisition trial, the scopol amine administration trial, and the regeneration trial.
Abstract
It is intended to clarify that silkworm and wild silkworm silk powders have an antidementia effect and an effect of improving memorization learning. Foods and drugs containing silkworm and wild silkworm silk powders are administered to mammals including humans.
Description
P 漏 2/09051 P leak 2/09051
明 細 書 カイコおよび野蚕のシルクパゥダーを含有させ抗痴呆効果ならびに記憶 学習向上を目的とする食品および医薬品 技術分野 Description Foods and pharmaceuticals containing silk powder of silkworms and wild silkworms to improve anti-dementia effects and improve memory learning
本発明は、 ヒトを含めた哺乳動物の抗痴呆効果ならびに記憶学習効果の 向上に利用する方法に関する。 技術背景 The present invention relates to a method for improving the anti-dementia effect and the memory learning effect of mammals including humans. Technology background
カイコおよび野蚕のシルクパゥダーは、 各種の製造技術で粉末化されて おり、 その低分子粉末化されたもののァミノ酸構成はフイブ口インタンパ ク質であることから既知のアミノ酸構成物である。 その利用法として、 食 品ならびに化粧品などに活用されている。 Silkworm and silkworm silk powders are pulverized by various manufacturing techniques, and the amino acid composition of the low molecular weight pulverized protein is a known amino acid composition because it is a protein at the mouth of the fiber. It is used for foods and cosmetics as its usage.
しかし、 いまだにカイコおよび野蚕のシルクパウダーに抗痴呆効果なら びに記憶学習向上効果があるということについては明らかにされていない。 発明が解決しょうとする課題 However, it has not yet been clarified that silk powder of silkworms and wild silkworms has an anti-dementia effect and an effect of improving memory and learning. Problems to be solved by the invention
そこで、 グリシン、 ァラニン、 セリン、 チロシンなどのフイブ口インタ ンパク質の構成アミノ酸が豊富に存在することから、 カイコおよび野蚕の シルクパゥダーに抗痴呆効果ならびに記憶学習向上効果が期待される。 Therefore, since the amino acids constituting the protein of the fibular mouth such as glycine, alanine, serine, and tyrosine are abundant, anti-dementia effects and memory learning improvement effects are expected for silkworms and silkworm wild silkworms.
課題を解決するための手段 Means for solving the problem
既知の製造法 (酸加水分解、 酵素加水分解) に従って作製したカイコお よび野蚕シルクパウダーをマウス (5週齢の ICR系雌性) に水溶液として 経口的に自由摂取させ、 対照区として、 水道水とゥシ血清アルブミン (ブ ラシ-ポとして採用) 水溶液を経口投与する。 発明の開示 Silkworms and wild silkworm silk powder prepared according to known production methods (acid hydrolysis, enzymatic hydrolysis) were allowed to freely ingest mice (five-week-old ICR female) orally as an aqueous solution, and tap water was used as a control.ゥ Serum albumin (adopted as brush-po) Oral administration of aqueous solution. Disclosure of the invention
本発明は、 以上説明したような形態で実施され、いかに記載されるような 効果を泰する。 The present invention is embodied in the form described above, and achieves the effects described below.
カイコならびに野蚕からのシルクパウダーを含有させた食品および医薬 品をヒトを含めた哺乳動物に投与することにより、 抗痴呆効果および記憶 学習効果を得ることができる。
T JP02/09051 By administering foods and medicines containing silk powder from silkworms and wild silkworms to mammals including humans, an anti-dementia effect and a memory learning effect can be obtained. T JP02 / 09051
2 図面の簡単な説明 2 Brief description of drawings
図 1摂取開始から 30日後にステップスルー型受動回避実験を 2日間行つ た成果図である。 発明を実施するための最良の形態 Fig. 1 This is the result of performing a step-through passive avoidance experiment for two days 30 days after the start of ingestion. BEST MODE FOR CARRYING OUT THE INVENTION
摂取開始から 30日後にステップスルー型受動的回避実験を 2日間行うも のである。 Thirty days after the start of ingestion, a step-through passive avoidance experiment is performed for two days.
受動的回避反応として、マウスを水区 (n=28)、シルクパウダー区 (n=31)、 牛血清アルブミン区(n=22)、 の 3グループに分ける。 For passive avoidance, mice are divided into three groups: water (n = 28), silk powder (n = 31), and bovine serum albumin (n = 22).
実験 1日目は、 前獲得試行測定 15分後にギロチンドアを閉めている明室 にマウスを入れる。 30秒後にドアを開け、 暗室に入るまでの時間を測定し On the first day of the experiment, place the mouse in the light room with the guillotine door closed 15 minutes after the pre-acquisition trial measurement. After 30 seconds open the door and measure the time to enter the darkroom
(以下、 獲得試行とする)、 入ったらドアを閉め電気刺激 (0. 5Ma、 4秒)を 与える。 なお、 暗室に入るまでの時間はマウスの後ろ足が完全に入った時 点で暗室に進入したものとして測定する。 24時間後 (実験 2日目) に、 ド ァを閉めている明室にマウスを入れる。 30秒後にドアを開け、 暗室に入る までの時間を測定する(以下、 投与前試行とする)。 投与前試行が 180秒以 下であったマウスは、 基準不達成マウスであるとして以後の再生試行は行 わない。 (Hereinafter, it will be referred to as an acquisition attempt), and upon entry, close the door and apply electrical stimulation (0.5 Ma, 4 seconds). The time to enter the darkroom is measured assuming that the mouse enters the darkroom when the hind legs of the mouse have completely entered. Twenty-four hours later (day 2 of the experiment), the mouse is placed in the light room with the door closed. After 30 seconds, open the door and measure the time it takes to enter the darkroom (hereinafter referred to as pre-dose trial). Mice with a pre-administration trial of less than 180 seconds are considered non-achievement mice and will not be subjected to subsequent regeneration trials.
次に、 一時的な痴呆を起す scopolamineを皮下注射し、 15分後にドアを 閉めている明室にマウスを入れ、 30秒後にドアを開け暗室に入るまでの時 間を測定する (以下、 再生試行とする)。 この実験では、 ノンパラメ卜リック 分析でデータ解析を行う。 同じ郡内の検定は Wilcoxonの符号順位検定、 異 なる群の間の検定は Mann-Whitneyの U検定を用いて有意差を調べる。 図 1に示す実施例は、 獲得試行、 scopol amine投与前試行、 そして再生試 行における記憶能 (秒) の結果である。 その結果、 scopo l amineを体重 lkg あたり 0. 5mg各マウスに投与し一時的な痴呆を起させたところ、 シルクパ ウダ一群と水道水ならびにゥシ血清アルブミンの間で、 再生試行において 反応潜時の有意差が認められる。 * く 0. 01, く 0. 05は、 再生試行における シルクパウダー群として他の 2グループで有意な差が認められる (Mann-Whi tneyの U検定)。 ## 0. 01は、 3グループの投与前試行と再生試 行の間で有意な差が認められる(Wi lcoxenの符号順位検定)。 Next, scopolamine, which causes temporary dementia, is injected subcutaneously, and 15 minutes later, the mouse is placed in a light room with the door closed, and 30 seconds later, the time until the door is opened and a dark room is measured (hereinafter referred to as reproduction) Trial). In this experiment, data analysis is performed using nonparametric analysis. Tests within the same county use the Wilcoxon signed rank test, and tests between different groups use the Mann-Whitney U test to find significant differences. The example shown in FIG. 1 is the result of the memory ability (sec) in the acquisition trial, the scopol amine administration trial, and the regeneration trial. As a result, when 0.5 mg / kg body weight of scopol amine was administered to each mouse to cause temporary dementia, the response latency in the regeneration trial was increased between the silk powder group and the tap water and the serum albumin. A significant difference is observed. * Ku 0.01 and Ku 0.05 show significant differences between the other two groups in the silk powder group in the regeneration trial (Mann-Whitney U test). ## 0.01 indicates a significant difference between the pre-dose trials and the regeneration trials in the three groups (Wilcoxen's signed rank test).
すなわち、 マウス行動実験においてシルクパウダー経口投与によって、 一時的な痴呆を抑える効果を有する。
That is, oral administration of silk powder in a mouse behavioral experiment has the effect of suppressing temporary dementia.
Claims
1 . カイコや野蚕のシルクパウダ一は、 主にグリシン、 ァラニン、 セリン、 チロシンのアミノ酸の繰り返し配列から構成されるフィプロインタンパク 質で、 各種の製造処理で低分子粉末化 (遊離アミノ酸とオリゴペプチドか ら構成) された既知のア請ミノ酸構成に基づく生産物である。 これを利用す ることにより、 抗痴呆効果ならびに記憶学習向上のために食品および医療 分野への応用開発。 1. Silk powder of silkworms and wild silkworms is a fiproin protein composed mainly of repeating amino acids of glycine, alanine, serine, and tyrosine. It is made into low molecular powder by various manufacturing processes (free amino acids and oligopeptides). The product is based on a known amino acid composition. By utilizing this, we will develop applications in the food and medical fields to improve anti-dementia effects and improve memory and learning.
2 . カイコおよび野蚕のシルクパのゥダ一に抗痴呆効果ならびに記憶学習向 上効果があるということについては明らかにされていない。 そこで、 グリ シン、 ァラニン、 セリン、 チロシンなどのフイブ口インタンパク質の構成 囲 2. It has not been clarified that silk parrots of silkworms and wild silkworms have anti-dementia effects and memory-learning effects. Therefore, the composition of the fibrillary in-proteins such as glycine, alanine, serine, and tyrosine is considered.
アミノ酸が豊富に存在することから、 カイコおよび野蚕のシルクパウダ一 に抗痴呆効果ならびに記憶学習向上を有することを特徴とする方法。
A method characterized by having an anti-dementia effect and improving memory and learning in silk powder of silkworms and wild silkworms due to abundance of amino acids.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002332302A AU2002332302A1 (en) | 2002-04-24 | 2002-09-05 | Foods and drugs containing silkworm and wild silkworm silk powder for antidementia effect and improving memorization learning |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-158295 | 2002-04-24 | ||
JP2002158295A JP2003310211A (en) | 2002-04-24 | 2002-04-24 | Food and medicine for improving antidement effect and memory learning comprising silkworm and wild silkworm powder |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003090775A1 true WO2003090775A1 (en) | 2003-11-06 |
Family
ID=29267853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/009051 WO2003090775A1 (en) | 2002-04-24 | 2002-09-05 | Foods and drugs containing silkworm and wild silkworm silk powder for antidementia effect and improving memorization learning |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2003310211A (en) |
AU (1) | AU2002332302A1 (en) |
WO (1) | WO2003090775A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006014033A1 (en) | 2004-07-31 | 2006-02-09 | Brainguard Co., Ltd. | Silk peptide improving neuroprotective and neurofunctional effects and a method of its preparation |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009280503A (en) * | 2008-05-19 | 2009-12-03 | Iwate Univ | Pharmacological use of cocoon of cricula trifenestrata |
JP2012017287A (en) * | 2010-07-07 | 2012-01-26 | Iwate Univ | Therapeutic agent for senile disease |
JP2012040010A (en) * | 2011-09-14 | 2012-03-01 | Biogrand Co Ltd | Use of composition as additive for food or functional food |
KR102092586B1 (en) * | 2018-05-23 | 2020-03-24 | 대한민국(농촌진흥청장) | Composition for improving memory or composition for preventing and treating Alzheimer's dementia containing boiled silkworm products having silk protein |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04267861A (en) * | 1991-02-19 | 1992-09-24 | Nagahama Sangyo Kk | Milk powder-containing dressing and production thereof |
JP2000093091A (en) * | 1998-09-25 | 2000-04-04 | Gakuei O | Wild silkworm water-soluble silk powder and its production |
JP2000201643A (en) * | 1999-01-11 | 2000-07-25 | Eiko:Kk | Pickled ume containing silk protein hydrolyzate added thereto and its production |
-
2002
- 2002-04-24 JP JP2002158295A patent/JP2003310211A/en active Pending
- 2002-09-05 WO PCT/JP2002/009051 patent/WO2003090775A1/en active Application Filing
- 2002-09-05 AU AU2002332302A patent/AU2002332302A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04267861A (en) * | 1991-02-19 | 1992-09-24 | Nagahama Sangyo Kk | Milk powder-containing dressing and production thereof |
JP2000093091A (en) * | 1998-09-25 | 2000-04-04 | Gakuei O | Wild silkworm water-soluble silk powder and its production |
JP2000201643A (en) * | 1999-01-11 | 2000-07-25 | Eiko:Kk | Pickled ume containing silk protein hydrolyzate added thereto and its production |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006014033A1 (en) | 2004-07-31 | 2006-02-09 | Brainguard Co., Ltd. | Silk peptide improving neuroprotective and neurofunctional effects and a method of its preparation |
EP1773864A1 (en) * | 2004-07-31 | 2007-04-18 | Biogrand Co., Ltd. | Silk peptide improving neuroprotective and neurofunctional effects and a method of its preparation |
EP1773864A4 (en) * | 2004-07-31 | 2009-02-18 | Biogrand Co Ltd | Silk peptide improving neuroprotective and neurofunctional effects and a method of its preparation |
AU2004322006B2 (en) * | 2004-07-31 | 2012-05-24 | Brainguard Co., Ltd. | Silk peptide improving neuroprotective and neurofunctional effects and a method of its preparation |
Also Published As
Publication number | Publication date |
---|---|
JP2003310211A (en) | 2003-11-05 |
AU2002332302A1 (en) | 2003-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Therapeutic effects of lentinan on inflammatory bowel disease and colitis‐associated cancer | |
Sugahara et al. | Differences between live and heat-killed bifidobacteria in the regulation of immune function and the intestinal environment | |
Córdova-Dávalos et al. | Glycomacropeptide bioactivity and health: a review highlighting action mechanisms and signaling pathways | |
CN1045391C (en) | Oral delivery system | |
DE69532760T2 (en) | AGENTS FOR THE ADMINISTRATION OF ANTIGENS | |
JP3769003B2 (en) | Intermediates of final glycation products and inhibition after Amadori transition | |
Landy et al. | Immunological Tolerance: A Reassessment of Mechanisms of the Immune Response | |
PL198958B1 (en) | Atherapeutic agent containing botuline neurotoxin | |
JPH06508371A (en) | Orally administrable therapeutic protein and its production method | |
JP5096173B2 (en) | Rheumatoid arthritis inhibitor for oral intake | |
JP2010520302A (en) | Bacterial extract for respiratory disorders and method for producing the same | |
CN109310736A (en) | For inducing satiety and extending the pharmaceutical composition and food compositions based on hafnia alvei of satiety | |
KR20020084066A (en) | Compositions and Methods for Treatment of Allergic Disorders | |
WO2003090775A1 (en) | Foods and drugs containing silkworm and wild silkworm silk powder for antidementia effect and improving memorization learning | |
JPH08502498A (en) | Hypoallergenic protein | |
CN105534949A (en) | Duloxetine hydrochloride enteric mini-pill preparation | |
Cook et al. | Isolation and partial characterization of a pentraxin-like protein with complement-fixing activity from snapper (Pagrus auratus, Sparidae) serum | |
BR9910606A (en) | Multiparticular dosage form with programmed and pulsed release and its preparation process | |
Huang et al. | Advances in the study of probiotics for immunomodulation and intervention in food allergy | |
US5951984A (en) | Method for inducing immunological tolerance, immunological tolerance inducing food kit, and immunological tolerance inducer kit | |
JPH09241177A (en) | Intestinal tract protecting agent | |
ES2686875T3 (en) | Exopolysaccharide of the bacterium Shigella sonnei, method to produce it, vaccine and pharmaceutical composition containing it | |
Zuo et al. | Separation of growth-stimulating peptides for Bifidobacterium from soybean conglycinin | |
JP2020200288A (en) | Agent for preventing or improving osteoarthritis | |
WO2002072629A1 (en) | Immunopotentiators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN ID IN KR US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |